A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary) ; Cyclophosphamide; Fludarabine
- Indications Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Adaptimmune
- 09 Nov 2017 According to an Adaptimmune media release, updated results of all cohorts of the study were presented at the annual CTOS meeting.
- 09 Nov 2017 Results published in an Adaptimmune media release.
- 03 Nov 2017 According to an Adaptimmune media release, data from the study will be presented at the upcoming CTOS meeting 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History